Tag:
NPS Pharmaceuticals
Latest Headlines
Latest Headlines
NPS begins to rack up sales of pricey SBS drug
NPS Pharmaceuticals ($NPSP) racked up the first quarterly score on its $295,000-a-year treatment for short bowel syndrome, claiming early traction for Gattex. To be sure, the numbers are small: 42 patients and 160 prescriptions in Q1.
NPS Pharma goes global with $80M deal to buy back Takeda's Gattex rights
NPS Pharmaceuticals has locked up the global rights to Gattex. The biotech bought back the ex-U.S. rights to its newly approved orphan drug (teduglutide) alongside another drug program close to a U.S. filing for rare cases of hypoparathyroidism, handing over $50 million in stock--a 7% equity stake in the company--with another $30 million on the table if the company hits a key sales milestone.
Last-minute drive at FDA added 6 new drug approvals
Our readers who regularly check our website know that we kept up with the news online. But for everyone else, here's a roundup of the regulatory actions you may have missed.
NPS Pharma bags FDA approval for bowel drug
The FDA has stamped an approval on NPS Pharmaceuticals' Gattex for treating patients with short bowel syndrome. The approval sets the stage for the U.S. launch of the company's lead drug and adds to U.S. regulators' impressive tally of more than 30 new drug nods in 2012.
FDA advisers back NPS Pharma's orphan bowel drug
If all goes as planned for NPS, the FDA will heed the advice of its panel of non-agency experts and stamp an approval on the drug before the end of the year.
NPS Pharma shares jump on upbeat FDA review of Gattex
NPS Pharmaceuticals got a big boost this morning when the FDA issued an upbeat preview of its short bowel syndrome drug Gattex, endorsing the developer's efficacy claims and key aspects of the risk evaluation and mitigation strategy it proposed to manage a potential cancer risk, among other safety issues.
NPS wraps another positive PhIII study as parathyroid drug impresses
A week after giving investors a Halloween scare with the news of two cancer deaths in a critical trial of Gattex , NPS Pharmaceuticals ( $NPSP ) followed up with positive top-line results from a pivotal
NPS Pharma shares sink after cancers reported in patients on bowel drug
NPS Pharmaceuticals gave investors a reason to run yesterday, but at least one analyst says today that the reaction was too much. The Bedminster, NJ-based developer said that three patients at sites
NPS soars on positive Ph3 data for orphan SBS drug
NPS Pharmaceuticals ( $NPSP ) says that it's on track to file for regulatory approval of Gattex after a late-stage study involving 86 patients demonstrated promising results for reducing the need for
GSK ends NPS's osteoporosis drug study
Bad news for NPS Pharmaceuticals: the company announced late Thursday that its partner GlaxoSmithKline would abandon a Phase II study of Ronacalaret, an osteoporosis drug. According to SEC filings
